The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Long-Term Follow-up of the West of Scotland Coronary Prevention Study
Open accessAbstract
BACKGROUND: The West of Scotland Coronary Prevention Study was a randomized clinical trial comparing pravastatin with placebo in men with hypercholesterolemia who did not have a history of myocardial infarction, with an average follow-up of approximately 5 years. The combined outcome of death from definite coronary heart disease or definite nonfatal myocardial infarction was reduced from 7.9 to 5.5% (P<0.001) in the treatment group. Extended follow-up data were obtained for approximately 10 years after completion of the trial. METHODS: For the survivors of the trial, all deaths, hospitalizations and deaths due to coronary events and stroke, and incident cancers and deaths from cancer were tracked with the use of a national computerized record-linkage system. The results were analyzed with time-to-event analyses and use of Cox proportional-hazards models. RESULTS: Five years after the trial ended, 38.7% of the original statin group and 35.2% of the original placebo group were being treated with a statin. In the period approximately 10 years after completion of the trial, the risk of death from coronary heart disease or nonfatal myocardial infarction was 10.3% in the placebo group and 8.6% in the pravastatin group (P=0.02); over the entire follow-up period, the rate was 15.5% in the placebo group and 11.8% in the pravastatin group (P<0.001). Similar percentage reductions were seen in the combined rate of death from coronary heart disease and hospitalization for coronary events for both periods. The rate of death from cardiovascular causes was reduced (P=0.01), as was the rate of death from any cause (P=0.03), over the entire follow-up period. There were no excess deaths from noncardiovascular causes or excess fatal or incident cancers. CONCLUSIONS: In this analysis, 5 years of treatment with pravastatin was associated with a significant reduction in coronary events for a subsequent 10 years in men with hypercholesterolemia who did not have a history of myocardial infarction.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The effect of blood-pressure reduction on cardiovascular end points usually occurs within months, 26,27 whereas the effect of lipid lowering is evident after 1 to 2 years.8,28,29”
From Effect of a multifactorial intervention on mortality in type 2 diabetes (2008) · cites this paper as [26]
In the citing paper
“Whereas much of the research has been conducted on aerobic exercise, increasing amounts of evidence from the general population indicates that strength and resistance training or 'high intensity interval training can produce a multitude of beneficial effects, for both metabolic and mental health.288-290”
From The Lancet Psychiatry Commission: a blueprint for protecting physical health in people with mental illness (2019) · cites this paper as [288]
Citations
Cites
Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia
Shepherd, J., Cobbe, S. M., Ford, I., Isles, C. G., Lorimer, A. R., Macfarlane, P. W., McKillop, J. H., & Packard, C. J. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511163332001 · Cited by 7,449
Sacks, F. M., Pfeffer, M. A., Moye, L. A., Rouleau, J. L., Rutherford, J. D., Cole, T. G., Brown, L., Warnica, J. W., Arnold, J. M. O., Wun, C.-C., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199610033351401 · Cited by 7,439
(1998) · New England Journal of Medicine · doi:10.1056/nejm199811053391902 · Cited by 5,261
PREVENTION OF CORONARY HEART DISEASE WITH PRAVASTATIN IN MEN WITH HYPERCHOLESTEROLEMIA
Hepherd, J. A. S., Obbe, S. T. M. C., Ord, I. A. F., Sles, C. H. G. I., Orimer, A. R. O. L., Acfarlane, P. E. W. M., Illop, J. A. H. M. C. K., Ackard, C. H. J. P., & Roup, S. T. G. (1995) · Cited by 3,453
Nissen, S. E., Nicholls, S. J., Sipahi, I., Libby, P., Raichlen, J. S., Ballantyne, C. M., Davignon, J., Erbel, R., Fruchart, J. C., Tardif, J.-C., et al. (2006) · JAMA · doi:10.1001/jama.295.13.jpc60002 · Cited by 2,047
Jukema, J., Bruschke, A. V., van Boven, A. J., Reiber, J., Bal, E., Zwinderman, A., Jansen, H., Boerma, G., van Rappard, F. M., & Kong, L. I. (1995) · Circulation · doi:10.1161/01.cir.91.10.2528 · Cited by 911
Pravastatin, lipids, and atherosclerosis in the carotid arteries (PLAC-II)
Crouse, J. R., Byington, R. P., Bond, M. G., Espefand, M. A., Craven, T. E., Sprinkle, J. W., McGovern, M. E., & Furberg, C. D. (1995) · The American Journal of Cardiology · doi:10.1016/s0002-9149(99)80580-3 · Cited by 607
Dale, K. M., Coleman, C. I., Henyan, N. N., Kluger, J., & White, C. M. (2006) · JAMA · doi:10.1001/jama.295.1.74 · Cited by 600
Antibodies against MICA Antigens and Kidney-Transplant Rejection
Zou, Y., Šťastný, P., Süsal, C., Döhler, B., & Opelz, G. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa067160 · Cited by 452
Pitt, B., Mancini, G. B. J., Ellis, S. G., Rosman, H., Park, J.-S., & Mcgovern, M. E. (1995) · Journal of the American College of Cardiology · doi:10.1016/0735-1097(95)00301-0 · Cited by 424
The Scottish Record Linkage System.
Kendrick, S. W., & Clarke, J. (1993) · PubMed · Cited by 377
Four-year Follow-up of a Prospective Trial of HLA and MICA Antibodies on Kidney Graft Survival
Terasaki, P., Ozawa, M., & Castro, R. M. P. (2007) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2006.01644.x · Cited by 362
Strandberg, T. E., Pyörälà, K., Cook, T. J., Wilhelmsen, L., Færgeman, O., Þorgeirsson, G., Pedersen, T. R., & KJEKSHUS, J. K. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16936-5 · Cited by 329
Deprivation and mortality in Scotland, 1981 and 1991
McLoone, P., & Boddy, F. A. (1994) · BMJ · doi:10.1136/bmj.309.6967.1465 · Cited by 247
Statins and Prostate Cancer Risk: A Case-Control Study
Shannon, J., Tewoderos, S., Garzotto, M. G., Beer, T. M., Derenick, R., Palma, A., & Farris, P. E. (2005) · American Journal of Epidemiology · doi:10.1093/aje/kwi203 · Cited by 231
Jaime, J., Klittich, W. S., McGuire, A. J., Ford, I., Norrie, J. D., Pettitt, D., McMurray, J. J. V., & Shepherd, J. (1997) · BMJ · doi:10.1136/bmj.315.7122.1577 · Cited by 203
HLA Antibody Identification With Single Antigen Beads Compared To Conventional Methods
El-Awar, N. R., Lee, J., & Terasaki, P. I. (2005) · Human Immunology · doi:10.1016/j.humimm.2005.07.005 · Cited by 130
(1995) · Journal of Clinical Epidemiology · doi:10.1016/0895-4356(95)00530-7 · Cited by 122
A coronary primary prevention study of Scottish men aged 45?64 years: Trial design
(1992) · Journal of Clinical Epidemiology · doi:10.1016/0895-4356(92)90068-x · Cited by 85
Detection of Antibodies to HLA-DP in Renal Transplant Recipients Using Single Antigen Beads
Qiu, J., Cai, J., Terasaki, P. I., El-Awar, N. R., & Lee, J.-H. (2005) · Transplantation · doi:10.1097/01.tp.0000181384.49832.3a · Cited by 62
Screening experience and baseline characteristics in the West of Scotland coronary prevention study
* (1995) · The American Journal of Cardiology · doi:10.1016/s0002-9149(99)80135-0 · Cited by 61
Research works printed but not linked: 2
- 1994, Lancet, 344, 1383
- Kendrick S, 1993, Health Bull (Edinb), 51, 72
Cited by
Sorted by citations
Effect of a multifactorial intervention on mortality in type 2 diabetes
Gæde, P., Lund-Andersen, H., Parving, H.-H., & Pedersen, O. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0706245 · Cited by 3,465
Collaborators, C. T. T. (. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60367-5 · Cited by 2,833
Rosuvastatin and Cardiovascular Events in Patients Undergoing Hemodialysis
Fellström, B. C., Jardine, A. G., Schmieder, R. E., Holdaas, H., Bannister, K., Beutler, J., Chae, D.-W., Chevaile, A., Cobbe, S. M., Grönhagen-Riska, C., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810177 · Cited by 2,036
Self-citationFirth, J., Siddiqi, N., Koyanagi, A., Siskind, D., Rosenbaum, S., Galletly, C., Allan, S., Caneo, C., Carney, R., Carvalho, A. F., et al. (2019) · The Lancet Psychiatry · doi:10.1016/s2215-0366(19)30132-4 · Cited by 1,531
Ford, I., & Norrie, J. (2016) · New England Journal of Medicine · doi:10.1056/nejmra1510059 · Cited by 1,405
Self-citation
Metadata
- Authors
- Ford, I., Murray, H., Packard, C. J., Shepherd, J., Macfarlane, P. W., & Cobbe, S. M.
- Affiliations
- University of Glasgow (GB)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2007-10-11
- Volume
- 357
- Issue
- 15
- Pages
- 1477-1486
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1973491874
- Cited by
- 416
- References
- 23
- Citations by year
- 2026: 4 · 2025: 6 · 2024: 7 · 2023: 7 · 2022: 9 · 2021: 9 · 2020: 7 · 2019: 14 · 2018: 23 · 2017: 26 · 2016: 29 · 2015: 19 · 2014: 34 · 2013: 46 · 2012: 28
- FWCI
- 36.61
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (submittedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
- Keywords
- pravastatin, statins, hypercholesterolemia, coronary artery disease, myocardial infarction, long-term follow-up, secondary prevention, cardiovascular mortality, cancer incidence, men
- MeSH terms
- Anticholesteremic Agents, Coronary Disease, Follow-Up Studies, Humans, Hypercholesterolemia, Male, Middle Aged, Myocardial Infarction, Pravastatin, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
